Meet the Team
Ian Smith MBE, BMedSc (Hons), MB, ChB
Chairman & Director
Ian founded Synexus, the world’s leading clinical Site Management Organisation and acted as Global Medical Director until 2014. Ian has been involved in over 1500 clinical trials in a variety of areas. In addition to the abundance of clinical expertise Ian brings to the team, he has a wealth of business experience, including the listing of Synexus Ltd onto AIM and the eventual sale to Lyceum Capital.
Dr. Liberty Foreman
CEO, Co-Founder & Director
As a highly motivated self starter Liberty has a passion for efficiency and believes that simplicity is the key to success. She provides the team with the drive and enthusiasm to build great products as well as being the original inventor of the algorithm behind DynamX-Bx.
Dr. Katherine Willetts
CSO, Co-Founder & Director
As a very diligent and thorough scientist, Katie is behind all of the cancer and disease biochemistry ensuring all our products are backed with good scientific meaning and interpretation. She is also a key individual in the protocol development and how our DynamX products are used.
Lance has spent over 15 years designing and building software and innovative technologies in highly regulated industries including medical, aerospace, security and defence. He has authored 9 patents – 6 granted and 3 pending.. He spent 8 years taking a medical imaging technology from initial concept to cleared medical device in Europe and the USA. He has a passion for start-ups, and in his graduate role in a university spin-out, he was a key member of a small team that took a fibre-optics spin-out through to acquisition.
Dr. Ilaria Idini
Scientific R&D Director
An experienced multidisciplinary researcher, having worked in the fields of neurobiology, physical chemistry and nuclear physics. Ilaria has had an accomplished academic career, with experience of a broad range of technologies, including previous experience in FTIR spectroscopy. She holds a PhD in Physical Chemistry from the University of Bath, and has spent the past three years in the University of Lund, Sweden.
Martin is Founder and Director of Max Accountants, an accountancy company offering tailored financial solutions to companies of all sizes. Prior to this Martin spent over 25 years working in the finance industry, predominantly for FTSE 100 companies, where he held a number of senior finance, sales and operations roles.
Clinical Trials Manager
Katy is an experienced clinical research professional with considerable local, national and international experience in medical device and pharmaceutical clinical trials. Katy has 9 years’ experience within the clinical research field and has worked for several organizations including charities, manufacturers and CROs (small and large) with their clinical trial projects. Katy has experience conducting feasibility, creating study documentation and protocols, training sites, monitoring and closing out sites.
Caroline has a strong background in business administration, project management and business development roles. The majority of her professional career has been spent in the construction industry, where her strong analytical and organisational skills have been used to win a number of tenders and external bids. She has an extremely proactive approach, ideally suited to the DynamX team.
Additional Board Members
Dr. Savvas Neophytou
Dr Savvas Neophytou is partner at Deepbridge Capital and Head of Life Sciences. Prior to joining Deepbridge in January 2016 Savvas enjoyed a 15 year career in the City, working as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon. As a highly acclaimed analyst he won multiple awards, most recently in 2015, when Savvas was ranked 2nd overall in the prestigious Reuters Starmine survey, a position he also held in 2014. In the same year, he was also runner up in the CityAM Analyst of the Year awards. Savvas holds a PhD in psychopharmacology from Nottingham University and a BSc (Hons) degree in pharmacology from Manchester University.
Working in the medical industry for the past 20 years Tim has vast expertise in commercial strategy, marketing and medical affairs. Tim was appointed to the board in April 2017 and will represent angel investors from London Business Angels, London Co-investment Fund, Angel Academe, Minerva, Wild Blue Cohort and Pemco Holding.
Prof. Karol Sikora MA, MBBChir, PhD, FRCR, FRCP, FFPM
Prof. Karol Sikora is Chief Medical Officer and founder board member of Proton Partners International, which is building five UK proton therapy centres. He held the same positions at Cancer Partners UK, which built 10 UK IMRT and IGRT radiotherapy centres before it was sold to Genesis Care in 2015. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine. He has also served as Chief of the WHO Cancer Programme. He is Dean of Medicine at Britain’s first independent Medical School at the University of Buckingham and a Fellow of Corpus Christi College, Cambridge, where he obtained a double first.
Prof. Laurence Lovat PhD, MBBS, BSc
Laurence is a professor of gastroenterology and biophotonics at UCL. He is chief investigator for a large multi-centre project to investigate he detection and treatment of oesophageal cancer, with key connections in the main specialist centres for oesophageal cancer in the UK. He is also special advisor to NICE (National Institute for Health and Care Excellence) who produce evidence based guidance and advice for the NHS and public health and social care services.
Prof. Anoop Chauhan MB ChB, FRCP, PhD
Prof. Chauhan is an NHS Clinician, Director of Research and Professor of Respiratory Medicine in Portsmouth. His research and clinical interests are in airways diseases particularly asthma and COPD, and is Chief Investigator on several trials that involve new devices, technologies and novel models of care (RESPECT-Meso, LASER, MISSION and SENSOR) funded by Asthma UK, British Lung Foundation, SBRI and NIHR-HTA among others. He is the Respiratory Lead for the Wessex AHSN and is overseeing a Respiratory Quality Improvement Programme throughout the region. He is a lead for the Wessex Asthma Network, bringing together a multidisciplinary team of specialists, generalists, commissioners, charities, innovators and patients to improve outcomes in asthma.
Prof. Tom Fearn
Tom is Head of Statistics at UCL and has over 30 years experience working with clinical research groups producing statistically robust data.
Dr. Simon Douglas
Simon has over 25 years’ experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions. Previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was sold to Agilent Technologies Inc and is currently a director of the antibody-based therapeutics Company Fusion Antibodies.